Gilead woos filgotinib clinical investigator from Stanford to lead the charge on NASH, inflammatory diseases

Amber Tong

Senior Editor

With an FDA OK for the use of filgotinib in rheumatoid arthritis expected to drop weeks from now, Gilead has recruited a new leader from academia to lead its foray into inflammatory diseases.

Mark Genovese — a longtime Stanford professor and most recently the clinical chief in the division of immunology and rheumatology — was the principal investigator in FINCH 2, one of three studies that supported Gilead’s NDA filing. In his new role as SVP, inflammation, he will oversee the clinical development of the entire portfolio.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Gilead woos filgotinib clinical investigator from Stanford to lead the charge on NASH, inflammatory diseases

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

Head of Regulated Labs Market Strategy

Benchling

San Francisco, CA, USA

The next generation of AI biotechs is here. Can they deliver on the hype?

Bristol Myers to shutter Bay Area cell therapy R&D facility as it eliminates jobs and costs

UCB makes major management changes; Bristol Myers’ ADC partner tops list of new CEOs

AbbVie beats first-quarter expectations, but Humira guidance leaves analysts confused

CHMP recommends eight new drug approvals, six label expansions

A New Precision Approach for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Gilead woos fil­go­tinib clin­i­cal in­ves­ti­ga­tor from Stan­ford to lead the charge on NASH, in­flam­ma­to­ry dis­eases

Senior Editor

Unlock this article instantly by becoming a free subscriber.

Benchling

San Francisco, CA, USA

Gilead woos filgotinib clinical investigator from Stanford to lead the charge on NASH, inflammatory diseases